UniQure NV

UniQure insiders buy big, signaling confidence in future gene‑therapy upside – but investors should weigh high volatility, FDA risk, and dilution concerns.

Insider buys at uniQure show senior execs backing its gene‑therapy pipeline—yet the stock faces analyst downgrades and a lawsuit, leaving investors weighing long‑term confidence against short‑term volatility.

CEO Matthew Kapusta’s March 2026 sale of 34,437 shares at $9.95 reflects routine tax‑covering, not a confidence loss – insiders remain long‑term holders while the market watches UniQure’s regulatory milestones and investor sentiment.

CEO insider sell‑off sparks debate on UniQure’s gene‑therapy outlook, raising questions about management confidence amid strong market gains.

Insider trades at uniQure reveal a cautious bullish stance: director Robert buys deep‑value shares, sells near‑peak prices, signaling confidence in upcoming gene‑therapy breakthroughs and potential rally.

Explore Kaye Jack’s pre‑planned uniQure NV buy‑sell trade, revealing insider confidence, premium sales, and potential upside amid FDA milestones.